View Older Stories View More Recent Stories

Sep 12, 2025 07:01AM Ionis expands adaptive event for neurological disease communities
Sep 12, 2025 07:00AM Ionis expands Surf Away+ event, marking 10 years of creating unique adaptive experiences for people with neurological diseases
Sep 9, 2025 07:00AM Ionis receives FDA breakthrough therapy designation for ION582
Sep 9, 2025 07:00AM Ionis receives U.S. FDA Breakthrough Therapy designation for ION582 in Angelman syndrome
Sep 8, 2025 04:00PM Ionis to host investors and analysts for Innovation Day 2025
Sep 2, 2025 04:00PM Ionis to present at upcoming investor conferences
Sep 2, 2025 07:01AM Ionis olezarsen shows 72% triglyceride reduction in Phase 3 studies
Sep 2, 2025 07:00AM Olezarsen significantly reduces triglycerides and acute pancreatitis events in landmark pivotal studies for people with severe hypertriglyceridemia (sHTG)
Aug 21, 2025 11:45AM DAWNZERA™ (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema
Jul 30, 2025 07:00AM Ionis reports second quarter 2025 financial results and highlights progress on key programs
Jul 25, 2025 07:15AM Ionis drug TRYNGOLZA gets EU committee approval recommendation for rare disease
Jul 25, 2025 07:15AM TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for familial chylomicronemia syndrome (FCS)
Jul 21, 2025 07:00AM Ionis reports positive HAE treatment switch study results
Jul 21, 2025 07:00AM Phase 3 OASISplus data demonstrating benefit of donidalorsen for HAE patients who switched from other prophylactics published in JACI In Practice
Jul 16, 2025 07:05AM Ionis to hold second quarter 2025 financial results webcast
Jun 25, 2025 07:31AM Ionis Pharmaceuticals (IONS) announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results
Jun 25, 2025 07:31AM Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results
Jun 12, 2025 09:01AM Ionis Pharmaceuticals (IONS) Announces Retirement of Chief Development Officer
Jun 12, 2025 09:00AM Ionis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026
Jun 11, 2025 07:02AM Ionis Pharmaceuticals (IONS): First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome
Jun 11, 2025 07:00AM First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome
May 19, 2025 07:01AM Ionis Pharmaceuticals (IONS) announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides
May 19, 2025 07:00AM Ionis announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides
May 6, 2025 07:05AM Ionis to host 2025 virtual Annual Meeting of Stockholders
Apr 30, 2025 07:00AM Ionis reports first quarter 2025 financial results
Apr 29, 2025 07:00AM New Harris Poll findings reveal HAE patients are unsatisfied with current prophylactic treatment options, with over 90% interested in trying new therapies
Apr 16, 2025 07:05AM Ionis to hold first quarter 2025 financial results webcast
Apr 3, 2025 07:05AM Ionis to host expert panel discussion on sHTG
Mar 31, 2025 07:05AM Ionis to present at upcoming investor conferences
Mar 26, 2025 07:02AM Ionis Pharmaceuticals (IONS) expands partnership with Sobi to include olezarsen commercialization outside the U.S.
Mar 26, 2025 07:00AM Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S.
Mar 11, 2025 06:13PM Ionis Pharmaceuticals (IONS) and Ono announce global license agreement
Mar 11, 2025 06:00PM Ionis and Ono announce global license agreement for sapablursen in polycythemia vera
Mar 10, 2025 07:02AM Ionis Pharmaceuticals (IONS) Announces WAINZUA approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy
Mar 10, 2025 07:00AM WAINZUA (eplontersen) approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy
Feb 25, 2025 07:05AM Ionis to present at upcoming investor conferences
Feb 20, 2025 07:03AM Ionis Pharmaceuticals (IONS): New positive donidalorsen data to be presented at AAAAI/WAO
Feb 20, 2025 07:00AM New positive donidalorsen data to be presented at AAAAI/WAO Joint Congress highlight sustained HAE attack rate reduction and disease control
Feb 19, 2025 07:00AM Ionis reports fourth quarter and full year 2024 financial results
Feb 5, 2025 07:05AM Ionis to hold fourth quarter and full year 2024 financial results webcast
Jan 13, 2025 08:00AM Ionis enters new chapter in 2025 as commercial-stage biotech with multiple independent product launches anticipated and continued late-stage pipeline momentum
Jan 8, 2025 04:11PM Ionis to present at 43rd Annual J.P. Morgan Healthcare Conference
Dec 19, 2024 06:30PM Ionis Pharmaceuticals (IONS) FDA approves TRYNGOLZA for adults with familial chylomicronemia syndrome
Dec 19, 2024 06:28PM TRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet
Nov 7, 2024 07:05AM Ionis to present at upcoming investor conferences
Nov 6, 2024 07:01AM Ionis Pharmaceuticals (IONS) Announces Pivotal Phase 3 Trial Design for ION582
Nov 6, 2024 07:01AM Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome
Nov 6, 2024 07:00AM Ionis reports third quarter 2024 financial results
Nov 4, 2024 09:45AM Ionis Pharmaceuticals (IONS) announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE
Nov 4, 2024 09:44AM Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE
View More Recent Stories View Older Stories